FDA顾问委员会否决膀胱癌药物致乌龙制药股价暴跌

iDoNews
May 22

周三,乌龙制药股价暴跌约47%,因FDA顾问委员会否决其膀胱癌疗法UGN-102。该药物针对复发性低级别中危非肌层浸润性膀胱癌,此前备受期待。FDA肿瘤药物顾问委员会以4票赞成、5票反对的结果认为其风险大于收益。尽管建议不具约束力,但FDA通常会参考委员会意见。乌龙制药表示,这一领域患者治疗选择有限,仍需更多支持。FDA将于2025年6月13日做出最终决定。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10